CUREAPP
6.5.2022 02:34:10 CEST | Business Wire | Press release
CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) was notified by the Ministry of Health, Labour and Welfare on April 26, 2022 that the company had received the medical device regulatory approval of an digital therapeutic app for Hypertension. This marks the first time a standalone software app supporting doctors and patients has received medical device regulatory approval in Japan, and is the first app addressing hypertension to be approved in the world. Preparations are now underway to receive reimbursement and launch the app in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005371/en/
Hypertension
Lifestyle modification is a vitally important part of treating essential hypertension, regardless of blood pressure classification. However, lifestyle modifications are dependent on the patient’s mindset and motivation, and workplace and home environment, and are difficult to maintain. Even with the involvement of a medical institution, successfully implementing such changes requires a significant amount of effort, and there are many limitations to what busy doctors can achieve.
Large numbers of patients suffer from hypertension in Japan, some 70% of these patients have either not achieved their anti-hypertensive goals, or have gone untreated. In addition, essential hypertension presents the single greatest risk factor of cerebrovascular diseases and heart diseases*1 , and medical expenses related to hypertension continues to increase year after year*2 .
*1
: Source: Guidelines for the Management of Hypertension 2019
*2
: FY2019 Ordinance of the Ministry of Health, Labour and Welfare General Overview of National Medical Expenditure
About this app
This app provides direct treatment guidance that has been tailored to each individual patient, including advice on diet, exercise, sleep, and other aspects of their lifestyle, and information intended to encourage behavioral improvements based on information entered by the patient, via their smartphone. Encouraging lifestyle changes and aiding patients acquire correct lifestyle habits helps patients make sustainable lifestyle changes, and is intended to bring about therapeutic efficacy in the form of lowering blood pressure by reducing salt intake and weight loss. The version of the app available to physicians allows physicians to check a patient’s daily progress toward implementing lifestyle changes, and is intended to contribute in a meaningful way toward improving the quality of medical care provided within a limited time frame.
The FY2022 revision of the national medical payment system added the “Addition of Medical Management of Software as a Medical Device, etc.”, and this marks the first case of a standalone software application acting as a doctor and patient aid receiving pharmaceutical approval. This is also the first time in the world medical device regulatory approval has been granted for DTx*3 in the field of hypertension.
*3 : Abbreviation of Digital Therapeutics. Software-based treatments.
Overview
Official name |
CureApp HT Hypertension Adjunctive Treatment App |
General name |
Hypertension Adjunctive Treatment Program |
Approval number |
30400BZX00100000 |
Intended use or effect |
Adjunctive treatments of essential hypertension in adults |
Date of approval |
April 26, 2022 |
Manufacture and sales |
CureApp, Inc. |
Summary of clinical trials for this product
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial
Kario et al. European Heart Journal, Volume 42, Issue 40, 21 October 2021, Pages 4111–4122, https://doi.org/10.1093/eurheartj/ehab559
Report on clinical trial results from the Company (CureApp) https://cureapp-en.blogspot.com/2021/09/cureapp-hypertension-therapeutics-app.html
Message from Kohta Satake, M.D. and Representative Director and CEO of CureApp, Inc.
We are proud to announce a new digital therapeutics solution for hypertension, following on from our digital therapeutics app for nicotine addiction. Hypertension is a disease that many suffer from in silence. It is a notoriously difficult disease to manage and treat, and one that requires fundamental lifestyle changes. Patients tend to have a low sense of urgency toward treating this disease while they still have few subjective symptoms of the disease, and it is difficult to maintain the level of behavioral change needed to address the underlying causes of the disease. The app acts as an adjunctive therapy in providing guidance during physicians consultations, and assists patients outside of consultations in approaching lifestyle changes in the correct way to get to the root cause. The app also provides physicians with a way to catch up on measures implemented during gaps in the patient’s treatment and their lifestyle habits, and makes it possible to provide better quality healthcare that is better tailored to the needs of the individual patient.
Digital therapeutics is set to become a standard form of treatment in Japan for both physicians and patients, and we will continue to look to develop DTx applications that treat other diseases.
About CureApp, Inc.
CureApp, Inc. is a MedTech venture that conducts research and development into the creation of medical device programs, which apply advanced software technology and medical evidence to treat illnesses, with the intent of manufacturing and distributing them. The Company is hard at work developing “therapeutic apps” - apps used to treat illnesses - in order to become the first in Japan to establish a new healthcare service centered on “producing a therapeutic effect to treat illnesses using an app”. In August 2020, CureApp was the first to receive medical device regulatory approval for a disease treatment app in Japan in the form of a nicotine addiction treatment app, which was later reimbursed under national health insurance in December of the same year.
Businesses CureApp is involved in
Nicotine addiction |
Received Medical Device Regulatory Approval in August 2020; reimbursed by National Healthcare insurance and prescriptions begin in December of the same year |
Hypertension |
Received Medical Device Regulatory Approval in April 2022 |
NASH
|
App currently in development and undergoing clinical trials with the University of Tokyo Hospital |
Alcohol addiction |
App currently in development with the National Hospital Organization Kurihama Medical and Addiction Center
|
Oncology |
Treatment app for breast cancer patients currently in development with DAIICHI SANKYO COMPANY, LIMITED. |
Chronic heart failure |
App under development with our partners at the YUMINO Medical Corporation |
In addition to the above, we provide mobile health programs for private companies through our “ascure Smoking Cessation Program” and “Specific Health Guidance ascure Smoking Cessation Program”, which leverages the knowledge garnered in the development of these digital therapeutics for medical institutions. These programs have been implemented at over 230 companies and health insurance societies. Looking ahead, we will look to sequentially rolling out this “Japanese-developed digital health solution” worldwide based on the model established in Japan.
CureApp, Inc. Company Profile
Representative Director and President |
Kohta Satake |
Head Office Address |
Kodenma-Cho YS building 4th floor 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001 |
U.S. Branch |
CureApp North America, Inc. |
Business activities |
Development of Software as a Medical Device (SaMD), mobile health-related services |
URL |
https://cureapp.co.jp/en/ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005371/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pretium Expands Real Estate Debt Platform19.11.2026 12:00:00 CET | Press release
Addition of Hilltop Capital Partners Enables the Firm to Deploy Capital to the U.K. Housing Market Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a hous
SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 12:00:00 CET | Press release
SRM and Ridgemont Continue a 30+ Year Track Record of Helping Banks, Credit Unions, and Fintech Companies Unlock Growth, Innovation, and Operational Efficiency Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Busine
Healthcare Accelerates AI Investment as Governance and Risk Shape the Path to Value19.11.2026 10:26:00 CET | Press release
HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory complexity, validation requirements, and organizational readiness HTEC, the global AI technology and engineering leader, today released new research examining how healthcare and life sciences organizations measure, track, and realize value from AI investments, as well as the risks and barriers preventing them from doing so at scale. The findings reveal that while investment continues to rise, organizations that successfully scale AI focus not only on technology, but also on the governance, workforce adoption, and operational foundations needed to track, prove, and realize impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119322683/en/ HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory c
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 10:00:00 CET | Press release
Twilio Segment gives Chelsea a more connected view of its global fanbase for real-time responses to personal interests and match moments on the pitch Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
